All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit Know AML.
The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Kura Oncology, Syndax, Abbvie, Thermo Fisher and Johnson & Johnson. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account to access:
Bookmark & personalize site content
Receive alerts for new content in your areas of interest
View AML content recommended for you
Cardiac safety profile of bleximenib in patients with KMT2Ar or NPM1m acute leukemias: Insights from EHA 2026
Do you know... According to the cAMeLot-1 and ALE1002 data presented at EHA2026, what was the key finding regarding the safety profile of bleximenib for NPM1m, KMT2Ar, or NUP98r acute leukemias?
Corrected QT (QTc) interval prolongation is a recognized risk factor for potentially fatal cardiac arrythmias; it is a safety consideration with currently approved menin inhibitors and is listed as a warning in their US Prescribing Information.1–3 Therefore, characterizing the cardiac safety profiles of emerging menin inhibitors is a key aspect of clinical development.1
The investigational menin inhibitor bleximenib is currently being evaluated in the phase I/II cAMeLot-1 (NCT04811560) trial, as monotherapy in patients with relapsed/refractory (R/R) KMT2A-rearranged (KMT2Ar), NPM1-mutated (NPM1m), or NUP98/214-rearranged (NUP98/214r) acute leukemia; and in the phase I/II ALE1002 (NCT05453903) trial, in combination with acute myeloid leukemia (AML)-directed therapies in patients with R/R or newly diagnosed (ND) KMT2Ar, NPM1m, or NUP98/214r AML.
Here, we present a visual abstract outlining analyses of the cardiac safety findings from the cAMeLot-1 and ALE1002 trials, which were presented by Marie Luise Hütter-Krönke at the European Hematology Association (EHA) 2026 Congress.
This educational resource is independently supported by Johnson & Johnson. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
.webp)